Pharmaceutical News

RSS

Study explains why some cancer vaccines are not as effective as hoped

A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.

31 Aug 2012

Addressing growing challenge of counterfeit drugs in developing world

"Many innovative solutions are being proposed to help tackle the spread of counterfeit drugs in developing countries," GlobalVoices reports. The blog includes highlights from several news articles and blog posts on the topic, including a number of solutions used to identify such drugs.

31 Aug 2012

S107 drug can prevent learning and memory deficits associated with stress-related disorders

Columbia University Medical Center (CUMC) researchers have identified a potential medical treatment for the cognitive effects of stress-related disorders, including post-traumatic stress disorder (PTSD).

31 Aug 2012

Study confirms link between hormone replacement therapy use and breast cancer

The Million Women Study is a study, conducted by UK researchers, of women's health analyzing data from more than one million women aged 50 and over. It is a collaborative project between Cancer Research UK and the National Health Service (NHS), with additional funding from the Medical Research Council (UK).

31 Aug 2012

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced today that LINZESS (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

31 Aug 2012

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

31 Aug 2012

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.

31 Aug 2012

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

31 Aug 2012

PD0325901 drug may hold potential to prevent neurofibromatosis 1 in children

A drug originally developed to stop cancerous tumors may hold the potential to prevent abnormal brain cell growth and learning disabilities in some children, if they can be diagnosed early enough, a new animal study suggests.

31 Aug 2012

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.

31 Aug 2012

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

30 Aug 2012

MU medicinal chemists create more potent, efficient weapon against cancer

Legend has it that Ralph Waldo Emerson once said, "Build a better mousetrap, and the world will beat a path to your door." University of Missouri researchers are doing just that, but instead of building mousetraps, the scientists are targeting cancer drugs. In a new study, MU medicinal chemists have taken an existing drug that is being developed for use in fighting certain types of cancer, added a special structure to it, and created a more potent, efficient weapon against cancer.

30 Aug 2012

UTMB to offer HPV vaccination against cervical cancer

University of Texas Medical Branch at Galveston's Dr. Abbey Berenson has been awarded a $1.2 million grant to start a program that will provide a vaccination against cervical cancer to many hundreds of low-income women who receive health care services at UTMB.

30 Aug 2012

RegeneRx’s Thymosin Beta 4 can promote recovery of diabetic peripheral neuropathy

RegeneRx Biopharmaceuticals, Inc. reports that U.S. researchers have found that Thymosin Beta 4 (Tβ4) promotes statistically significant recovery of peripheral neuropathy in type II diabetic mice including recovery of neurovascular dysfunction in the sciatic nerve and recovery of neurological function.

30 Aug 2012

Noven submits LDMP NDA with FDA to treat menopausal vasomotor symptoms

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has submitted to the U.S. Food & Drug Administration a New Drug Application (NDA) seeking approval to market low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms associated with menopause.

30 Aug 2012

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

30 Aug 2012

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Aerial BioPharma, a biopharmaceutical company focused on developing biologics and small molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development.

30 Aug 2012

Jobless working-age people with diabetes less likely to adhere to their medications

If you're diabetic or prone to diabetes, having a steady job appears to be good for your health, and not just because of the insurance coverage.

30 Aug 2012

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.

30 Aug 2012

ALK signs agreement to supply PRE-PEN to HealthTrust member facilities

ALK is pleased to announce that it has signed an agreement with HealthTrust Purchasing Group, LP to supply PRE-PEN (benzylpenicilloyl polylysine injection USP) the only FDA approved skin test for the diagnosis of penicillin allergy, to HealthTrust member facilities, including 1,400 acute care facilities, 10,600 ambulatory surgery centers, physician practices and alternate care sites.

30 Aug 2012

Pharmaceutical News

Study explains why some cancer vaccines are not as effective as hoped

Addressing growing challenge of counterfeit drugs in developing world

S107 drug can prevent learning and memory deficits associated with stress-related disorders

Study confirms link between hormone replacement therapy use and breast cancer

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

PD0325901 drug may hold potential to prevent neurofibromatosis 1 in children

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

MU medicinal chemists create more potent, efficient weapon against cancer

UTMB to offer HPV vaccination against cervical cancer

RegeneRx’s Thymosin Beta 4 can promote recovery of diabetic peripheral neuropathy

Noven submits LDMP NDA with FDA to treat menopausal vasomotor symptoms

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Jobless working-age people with diabetes less likely to adhere to their medications

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

ALK signs agreement to supply PRE-PEN to HealthTrust member facilities

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News